Press release
Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress
Prioritization of mRNA therapeutics pipeline extends cash runway into 2028 ARCT-032 (CF) Phase 2 interim data from first two cohorts expected in mid-2025
About this update from Arcturus Therapeutics Holdings Inc.
[{"type":"text","content":"\nPrioritization of mRNA therapeutics pipeline extends cash runway into 2028\n\nARCT-032 (CF) Phase 2 interim data from first two cohorts expected in mid-2025\n\nARCT-032 (CF) Phase 2 expected to complete enrollment by year end\n\nARCT-810 (OTC) Phase 2 interim data expected Q2 2025\n\nInvestor conference call at 4:30 p.m. ET today\n\n SAN DIEGO--(BUSINESS WIRE)--\nArcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the first quarter ended March 31, 2025, and provided corporate updates.\n\n“We are delighted with enrollment in our cystic fibrosis (CF) program, and the company is working diligently to provide meaningful Phase 2 interim data mid-year,” said Joseph Payne, President & CEO of Arcturus Therapeutics. “We are encouraged by the clinical progress of our CF and OTC programs, and given the current market conditions, we made a strategic decision to streamline resources to focus on our mRNA therapeutics pipeline.”\n\n“I am happy to report we have received the initial European Union (EU) approval milestone payment from our partnership with CSL,” said Andy Sassine, Chief Financial Officer of Arcturus. “I am also pleased to report that the cash runway now extends into 2028 with the re-allocation of resources to our therapeutics pipeline.”\n\nRecent Corporate Highlights\n\n\nArcturus is advancing enrollment of adult CF participants in the open label Phase 2 multiple ascending dose CF study (NCT06747858) with daily inhaled treatments of ARCT-032 over a period of 28 days and expects to complete enrollment by year end. The Company expects to provide Phase 2 interim data from the first two cohorts in mid-2025.\n\n\nArcturus continues to enroll participants in the open label Phase 2 OTC deficiency study (NCT06488313) with five intravenous infusions of ARCT-810 over a period of two months. The Company previously completed the dosing phase (N = 8; 0.3 mg/kg) of a placebo-controlled European study enrolling OTC deficient individuals. The Company expects to provide Phase 2 interim data in Q2 2025.\n\n\nIn April, Arcturus received U.S. FDA Fast Track Designation for ARCT-2304, an sa-mRNA vaccine candidate for P...